In the third quarter, First Citizens Bank & Trust Co. significantly increased its stake in Eli Lilly and Company by 58.8%, acquiring an additional 9,121 shares to bring its total holdings to 24,634 shares valued at approximately $18.8 million. During the same period, Commerzbank Aktiengesellschaft FI reduced its position by 1.8%, selling 741 shares to hold 39,787 shares with a valuation of roughly $30.4 million. These moves underscore continued confidence among large institutions—82.53% of the company’s stock remains owned by such investors—while highlighting tactical rebalancing as Eli Lilly’s market capitalization hovers near the trillion-dollar mark.

Eli Lilly reported third-quarter revenue of $17.6 billion, beating consensus estimates of $16.09 billion and representing a 53.9% year-over-year increase. Adjusted earnings per share stood at $7.02, surpassing analyst forecasts of $6.42 and driving a net margin of 30.99% alongside an impressive 109.52% return on equity. Reflecting the strength of its pipeline—anchored by leading products in oncology, diabetes, and immunology—the company issued full-year 2025 EPS guidance in the range of $23.00 to $23.70, well above street projections of approximately $23.48.

Demonstrating commitment to shareholder returns, Eli Lilly raised its quarterly dividend to $1.73 per share, up from $1.50, translating to an annualized payout of $6.92 and a payout ratio of 29.35%. The ex-dividend date is set for mid-February, with payment in early March. Analyst coverage remains overwhelmingly positive: among 26 firms surveyed, four rate the shares a ‘Strong Buy,’ eighteen a ‘Buy’ and four a ‘Hold,’ supporting a consensus target just above $1,170. This bullish outlook reflects confidence in the company’s robust financial performance, diversified pipeline and leadership in high-growth therapeutic markets.